DelveInsight’s “Glioblastoma Multiforme (GBM) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Glioblastoma market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Glioblastoma drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Glioblastoma treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Glioblastoma Multiforme (GBM): An Overview
Glioblastoma Multiforme (GBM) is the most frequently occurring type of primary tumor of the central nervous system (CNS) mostly in adults, and its poor prognosis has not been significantly improved despite the fact that innovative diagnostic strategies and new therapies have been developed.
GBMs can be classified into primary and secondary GBMs. Primary GBM occurs de novo without evidence of a less malignant precursor while Secondary GBM develops from initially low-grade diffuse astrocytoma (WHO grade II diffuse astrocytoma) or anaplastic astrocytoma (Grade III).
GBM is the most common and aggressive type of primary brain tumor in humans, accounting for 52% of all primary brain tumor cases and 20% of all intracranial tumors. GBM can present with focal or generalized signs due to mass effect, parenchymal infiltration, and destruction. Neurological symptoms of GBM include a headache that tends to worsen in the morning, vomiting, nausea, seizures, cognitive dysfunction, speech problems (difficulty in finding the right words), vision problems (abnormal eye movement), etc.
Glioblastoma Multiforme (GBM) Market Key Facts
According to the estimates, the highest market size of Glioblastoma is from the United States, in 2021.
Among the EU4 (Germany, France, Italy, Spain), and the UK, in which Germany has the maximum revenue share in 2021 while Spain has the lowest market share.
The market size of Glioblastoma in Japan is USD 58 million in 2021 which is expected to rise during the forecast period.
The epidemiology segment also provides the Glioblastoma epidemiology data and findings across the United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The Total Diagnosed Incident Population of Glioblastoma in the 7MM comprised 32,000+ cases in 2021.
The Gender-specific Diagnosed Incidence of Glioblastoma in the United States, in which maximum cases were recorded in the male population i.e., 7,705 in 2021, as compared to the female population.
Among the EU-4, the UK countries, Germany accounted for the highest number of Glioblastoma cases, followed by France, whereas Spain accounted for the lowest number of cases in 2021.
In Japan, the Type-specific Diagnosed Incidence of Glioblastoma in Japan was of two types in which maximum cases were recorded of Primary Glioblastoma/ IDH-wild Type 2,541 in 2021 and is anticipated to rise during the forecast period.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Glioblastoma pipeline therapies. It also thoroughly assesses the Glioblastoma market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Glioblastoma drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Glioblastoma Multiforme (GBM) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Glioblastoma epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Glioblastoma epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Glioblastoma Epidemiology, Segmented as –
Total Diagnosed Incident Population of Glioblastoma
Gender-specific Diagnosed Incidence of Glioblastoma
Type-specific Diagnosed Incidence of Glioblastoma
Age-specific Diagnosed Incidence of Glioblastoma
Diagnosed Incident Population based on Primary Site of Glioblastoma
Diagnosed Incident Population based on Histologic Classification of Glioblastoma Tumor
Glioblastoma Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Glioblastoma market or expected to be launched during the study period. The analysis covers the Glioblastoma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Glioblastoma drugs based on their sale and market share.
The report also covers the Glioblastoma pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Glioblastoma companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Glioblastoma Market Will Evolve and Grow by 2032 @
Glioblastoma Multiforme (GBM) Therapeutics Analysis
Treatment for GBM usually includes a combination of surgery, chemotherapy, radiation, or stereotactic radiosurgery. Surgery is usually one of the most important aspects of treatment, although rarely used alone. Since glioblastomas develop very rapidly, they are often difficult to remove in their entirety. Therefore, surgery is performed to achieve a maximum safe resection – removing as much of the tumor as possible while preserving the patient’s brain function and sparing healthy tissues. Residual cancer cells can be targeted with additional treatments, such as chemotherapy or radiation therapy, after surgery. Radiation therapy and chemotherapy usually follow surgery once the diagnosis or name of the tumor is determined. These treatments are called adjuvant treatments. Because this multispecialty approach can cause several side effects, steroids are often provided as another essential part of glioblastoma treatment, used to help alleviate the side effects of other therapies.
The first-line treatment of GBM involves drug therapy following surgery, which includes Temozolomide + Radiation Therapy and Temozolomide Monotherapy. While the second-line treatment for GBM includes Bevacizumab Monotherapy, Bevacizumab Combination Therapy, Temozolomide (Both as Combination and Monotherapy), and Other Systemic Therapies (Concomitant and Adjuvant).
To further improve the treatment scenario, several major pharma and biotech companies are developing therapies for Glioblastoma Multiforme (GBM). Currently, Oncotelic Therapeutics is leading the therapeutics market with its Glioblastoma Multiforme drug candidates in the most advanced stage of clinical development.
Glioblastoma Companies Actively Working in the Therapeutics Market Include
3-V Biosciences, ACADIA Pharmaceuticals, Acerta Pharma, Aivita Biomedical, Array Biopharma, Ascletis, AstraZeneca, Autotelic Therapeutics, Bayer, BioMimetix, BioNTech, Bristol Myers Squibb, Celgene Corporation, Chimerix, CNS Pharmaceutical, Cytogel, Denovo Biopharma, DNAtrix, Doule bond Pharmaceuticals, Eisai and Merck Sharp & Dohme, Enterome, Epitopoietic Research Corporation (ERC), Forma Therapeutics, Genenta Science, Immatics N.V, Immunomic Therapeutics, Imvax, Inovio Pharmaceuticals, Istari Oncology, Karyo Pharma, Karyopharm Therapeutics, Kazia Therapeutics, Kintara Therapeutics, Laminar Pharmaceuticals, Mayo Clinic, Medicenna Therapeutics, MedImmune, Merck, MimiVax, Neugate Theranostics, Northwest Therapeutics, Novartis, Noxxon Pharma, Oblato, Oncotelic Therapeutics, Orphelia Pharma, Pfizer, Philogen, Roche, SonALAsense, TME Pharma, VBI Vaccines, Xgene Pharmaceutical, Yumanity Therapeutics, and many others.
Emerging and Marketed Glioblastoma Therapies Covered in the Report Include:
Afatinib: Boehringer Ingelheim, AV-GBM-1: Aivita Biomedical, Avastin: Genentech, AZD1390: AstraZeneca, Crenolanib: AROG Pharmaceuticals, CYNK 001: Celularity, DCVax-L: Northwest Pharmaceuticals, Durvalumab (MEDI4736): MedImmune, G207: Treovir, ITI-1000 (pp65 DC Vaccine): Immunomic Therapeutics, LAM561 (2-OHOA): Laminar Pharmaceuticals, MDNA55: Medicenna Therapeutics, Ofranergene obadenovec (VB-111): VBL Therapeutics, ONC201: Chimerix, Onfekafuspalfa: Philogen, Paxalisib (GDC-0084): Kazia Therapeutics, PVSRIPO: Istari Oncology, Regorafenib: Bayer Healthcare, Research program: protein arginine N-methyltransferase 5 inhibitors: Jubilant Therapeutics, Selinexor (KPT-330): Karyopharm Therapeutics, Selinexor: Karyopharm Therapeutics, Tasadenoturev (DNX-2401): DNAtrix, Temodar/Temodal: Merck, Trabedersen: Oncotelic Therapeutics, Trans Sodium Crocetinate: Diffusion Pharmaceuticals, TVB2640:Ascletis Pharma, VAL-083 (Dianhydrogalactitol): Kintara Therapeutics, VBI-1901: VBI Vaccines, YTX7739: Yumanity Therapeutics, and many more.
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Glioblastoma Competitive Intelligence Analysis
4. Glioblastoma Market Overview at a Glance
5. Glioblastoma Disease Background and Overview
6. Glioblastoma Patient Journey
7. Glioblastoma Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Glioblastoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Glioblastoma Unmet Needs
10. Key Endpoints of Glioblastoma Treatment
11. Glioblastoma Marketed Therapies
12. Glioblastoma Emerging Drugs and Latest Therapeutic Advances
13. Glioblastoma Seven Major Market Analysis
14. Attribute Analysis
15. Glioblastoma Market Outlook (In US, EU5, and Japan)
16. Glioblastoma Companies Active in the Market
17. Glioblastoma Access and Reimbursement Overview
18. KOL Views on the Glioblastoma Market
19. Glioblastoma Market Drivers
20. Glioblastoma Market Barriers
22. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Obsessive-Compulsive Disorder Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Obsessive-Compulsive Disorder market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Obsessive-Compulsive Disorder market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States